Jim Cramer: We Need to Rerate Bristol-Myers
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said investors need to reassess shares of Bristol Myers amid reports that its lung cancer treatment had failed an important study.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said investors need to reassess shares of Bristol Myers (BMY) - Get Report amid reports that its lung cancer treatment had failed an important study. Shares dipped almost 17 percent. 'Bristol is correctly down - so now we have to rerate Bristol,' Cramer said.
